go-v.orgdoi

Pediatric trials of antihypertensive agents: impact of trial design and unique pediatric factors on efficacy end points

Kevin D. Hill, Patricia Y. Chu, Jennifer S. Li, Christoph Paul Vincent Hornik · Clinical Investigation · 2014

  • DOI 10.4155/cli.14.98
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2014

Abstract

There is an increasing prevalence of pediatric hypertension worldwide due to the growing epidemic of childhood obesity. Recent regulatory changes in the USA and Europe have stimulated major pediatric clinical trials of 16 different antihypertensive agents, leading to US FDA labeling of 10 of these drugs. With increased pediatric hypertension trial experience, trial designs have been refined and we now better understand factors associated with trial success, including the ability to differentiate a dose–response relationship.

The use of weight-based dosing and liquid formulation of study drug, selection of an appropriate dose range and appropriate blood pressure end points all increase the likelihood of pediatric trial success.

Open the resolved locator · 10.4155/cli.14.98

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 02:09 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.14.98
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.